Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Refractec’s ViewPoint Gains FDA Approval For Limited Diopter Range

This article was originally published in The Gray Sheet

Executive Summary

Refractec's eight direct sales reps immediately will begin marketing the ViewPoint CK system, which allows +1.0 to +2.25 diopters of presbyopia correction, as recommended by FDA's Ophthalmic Devices Panel
Advertisement

Related Content

AdvaMed 2005 Annual Meeting In Brief
AdvaMed 2005 Annual Meeting In Brief
Refractec CK Presbyopia Treatment Should Be Limited To 2.25D – FDA Panel
Refractec CK Presbyopia Treatment Should Be Limited To 2.25D – FDA Panel
Advertisement
UsernamePublicRestriction

Register

MT019987

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel